Trader consensus on Polymarket prices an 84.5% chance of no new WHO-designated COVID-19 variant of concern before 2027, driven by the absence of any such classification despite the recent emergence of highly mutated SARS-CoV-2 BA.3.2 ("Cicada") in over 30 U.S. states and 23 countries since late March 2026. This variant under monitoring shows immune evasion potential and faster spread—especially among children—but lacks evidence of increased severity, hospitalizations, or vaccine failure, with test positivity remaining low at around 3%. Broad population immunity from prior infections and updated boosters, coupled with ongoing genomic surveillance, underpins the "wisdom of crowds" favoring stability, though unexpected surges in transmission or deaths could shift odds ahead of year-end resolution.